USPTO serial 79181453
PLEXZYME
Reviewed by CopyMark Law Group
Reg. 5215651Status 739Renewal
- Filing date
- Status date
- Registration date
- Jun 6, 2017
- Examiner
- LAW, CHRISTOPHER M
- Law office
- GENERIC WEB UPDATE
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with PLEXZYME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $797*
Plus Government fees of $1,950
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Eveleigh NSW 2015, AU
Eveleigh NSW 2015, AU
Eveleigh NSW 2015, AU
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mainak H. Mehta
Mainak H. Mehta Procopio Cory Hargreaves & Savitch525 B Street, Suite 2200San Diego, CA 92101UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry, science, photography; chemicals used in agriculture, horticulture and forestry except fungicides, herbicides, insecticides, and parasiticides; chemical reagents and reactants in this class for non-medical purposes; enzymes for industrial purposes, namely, for use in the biotechnology industry; nucleic acid sequences, other than medical and veterinary purposes; nucleic recombinant acids; acids, namely, inorganic acids; organic acids for use in the biotechnology industry; DNA polymerase, other than medical and veterinary purposes; chemicals used in food processing and screening; chemicals used in environmental monitoring | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations and substances for the diagnosis of diseases or detection or identification of pathogens for medical and veterinary purposes; reagents for medical and veterinary use; nucleic acid amplification reagents for medical use; nucleic acid sequencing programs for medical use; chemical preparations containing enzymes for medical purposes for the diagnosis of diseases or detection or identification of pathogens; chemical preparations containing enzymes for pharmaceutical, veterinary and medical purposes for the diagnosis of diseases or detection or identification of pathogens; enzymes for pharmaceutical, veterinary and medical purposes; medical kits in this class consisting of catalytic DNA molecules and associated detection reagents for the diagnosis of diseases, for detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, and immune-suppression and immune disorders, for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; diagnostic reagents for medical or veterinary use; biological chemical test kits for medical laboratory use in analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression, immune disorders | ACTIVE | — |
| 010 | Surgical, medical and veterinary apparatus and instruments, namely, surgical apparatus and instruments for medical or veterinary use; diagnostic testing apparatus and instruments for medical purposes, namely, for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; point of care medical devices for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; medical screening apparatus in this class for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SpeeDx Pty Ltd
- Other trademarks owned by SpeeDx Pty Ltd
- Other trademarks owned by SpeeDx Pty Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named PLEXZYME
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 6, 2026 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Aug 7, 2025 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Feb 13, 2024 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Feb 13, 2024 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Feb 12, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 6, 2023 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Jun 6, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 28, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 14, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 14, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 6, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 6, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 21, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 21, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 17, 2017 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 10, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 1, 2017 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 1, 2017 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 1, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 13, 2017 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 10, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 1, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 1, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 1, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 1, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 1, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 16, 2016 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 1, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 1, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 1, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 16, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 16, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 16, 2016 | ALIE | ASSIGNED TO LIE | — |
| Aug 10, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 27, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 10, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 10, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 10, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 9, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 9, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 5, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 5, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 4, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |